New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

West Pharmaceutical Services, Inc.

WST

Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.

Revenue
+8.69%
EPS
+57.3%
Free cash flow
+12.3%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

390.56 6.13 −1.55%

After hours trading: 390.30, down 0.07%, last trade 5:54pm Eastern.

Market cap
$27.6B
P/E
43.5×
Fwd P/E FY26e
44.6×
Dividend yield
0.24%
F-score
8/9
ROIC
18.0%
Net debt / EBITDA
−0.8×
Payout ratio
0.1×

Where the cash went Q3 FY2026, quarter to Sep 30, 2026

Dividends and buybacks of $241.3M were more than free cash flow of $150.4M; the difference came from the lines below. Cash rose by $28.3M. Lines the picture does not name came to +$119.7M. What is a cash flow statement?

Free cash flow
$150.4M 79.4% of operating cash flow
Returned to shareholders
$241.3M 160.4% of free cash flow
Debt, net
−$500.0K repaid
Change in cash
+$28.3M over the period
Where the cash went, in millions of dollars
Operating cash flow189.5
Capital expenditures−39.1
Free cash flow150.4
Dividends−15.5
Buybacks, net−225.8
Debt repaid, net−0.5
Other+119.7
Change in cash28.3
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Operating cash flow$251M$90M$124M$190M
Capex−$76M−$43M−$43M−$39M
Free cash flow$175M$47M$81M$150M

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Net Income
214.00 154.00 138.80 132.10

+8 more quarters

Depreciation & Amortization
45.90 46.20 45.20 47.00
Non Cash Items (Other)
(51.10) 9.80 8.80 (9.70)
Change in other assets and liabilities
(19.30) (86.00) (102.90) 119.70
Operating Cash Flow
189.50 124.00 89.90 251.10
Capital expenditures
(39.10) (43.20) (42.70) (76.10)
Investing cash flow
78.90 (43.20) (42.70) (76.10)
Repayment/Issuance of Debt (Net)
(0.50) 49.60 (0.30) (0.30)
Equity Repurchase (Common, Net)
(225.80) (147.90) (292.60) 4.40
Dividends Paid (Total)
(15.50) (15.70) (15.80) (15.80)
Other financial activities
0.00 (50.80) — 0.00
Financing cash flow
(241.80) (164.80) (308.70) (11.70)
Exchange Rate Adjustment
1.70 (1.60) (8.40) (0.50)
Change in Cash
28.30 (85.60) (269.90) 162.80
Beginning Cash
0.00 0.00 791.30 0.00
Ending Cash
28.30 (85.60) 521.40 162.80
Stock Based Compensation
4.30 10.90 6.60 6.70
Dividends Paid (Common)
(15.50) (15.70) (15.80) (15.80)
Net Cash/Marketcap
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(19.30) (86.00) (102.90) 81.70
Issuance/Purchase of Shares
(225.80) (147.90) (292.60) 4.40

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026